Device Trial Radar · NCT06743113
Hypoxic Red Blood Cells in Sickle Cell Anemia
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Apr 1, 2029
Study completion Oct 1, 2029
Sponsor
- Lead sponsor
- HemanextNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Emory University; University of Connecticut; University of Pittsburgh Medical Center; Johns Hopkins University; University of Illinois Chicago; National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.
Conditions
- Sickle Cell Anaemia
- Sickle Cell Anemia Crisis
- Sickle Cell Anemia in Children
- Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions
Hemanext ONE SystemDevice
Hypoxic red blood cells
Conventional RBCsDevice
Conventional red blood cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- %HbA Rate of DeclineTime frame: Through study completion, an average of 14 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
New England Sickle Cell Institute, University of Connecticut
Farmington, Connecticut
Emory University School of Medicine
Atlanta, Georgia
University of Illinois at Chicago
Chicago, Illinois
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.